M alaria caused by the protozoan parasite Plasmodium falciparum is one of the leading causes of mortality and morbidity in humans worldwide (1) . Chloroquine (CQ) was initially a highly effective drug against this devastating disease (2). However, resistant strains of P. falciparum began to appear around 1950, and today practically all of the parasites are resistant to CQ (3) (4) (5) (6) (7) . This has become a major threat to global public health. Extensive research identified a CQ transporter, P. falciparum CQ resistance transporter (PfCRT), which functions in resistant but not wild-type strains of the parasite (2, (8) (9) (10) (11) (12) (13) (14) . The mutant transporter is expressed in the membranes of its digestive vacuoles (DV), excreting CQ from the vacuole and thus conferring resistance (15, 16) . The decrease in intravesicular CQ concentration also promotes conversion of highly toxic hematin to hemozoin, generating resistance to other antimalarial drugs in addition to CQ (2, 9, (17) (18) (19) (20) (21) (22) (23) . Therefore, it is important to clarify the transport mechanism of PfCRT to overcome drug resistance in malaria parasites (2, (9) (10) (11) . However, the role of CQ-sensitive PfCRT transport under physiological conditions and how CQ-resistant PfCRT gains the ability to transport CQ remain unclear.
Addressing the physiological relevance of PfCRT is a major issue in the area of infectious diseases. Attempts to obtain PfCRTdefective P. falciparum have been unsuccessful, suggesting that PfCRT is involved in DV transport processes that are essential for the parasites (2, 9) . As CQ is a divalent amine that can freely penetrate through lipid membranes in its neutral form, but becomes impermeable upon protonation, we hypothesized that PfCRT recognizes amphipathic amines as transport substrates and acts as a polyspecific organic cation transporter. Similar to the vacuoles of yeasts and plants, the DV of the malaria parasite establishes a proton motive force or an electrochemical gradient of protons across the membrane as the sum of interior acidic pH gradient (ΔpH) and inside-positive membrane potentials (Δψ) by electrogenic proton pumps, vacuolar H + -ATPase, and vacuolar H + -pyrophosphatase to supply energy to secondary active transporters (23) (24) (25) (26) (27) . Therefore, we also hypothesized that PfCRT may use the electrochemical gradient of protons as a driving force for transport.
Recently, we have developed a transporter assay system that includes overexpression, purification, and reconstitution of eukaryotic transporters (28) (29) (30) . The assay system enables us to study the mechanisms of action of transporters under defined ΔpH and Δψ.
In the present study, we applied this technique to PfCRT to determine the transport properties of CQ-sensitive and CQ-resistant PfCRTs.
Results and Discussion
To test the working hypothesis that PfCRT is a H + -coupled polyspecific organic cation transporter, we expressed and purified recombinant CQ-sensitive PfCRT 3D7 or PfCRT D10 by fusing a soluble Escherichia coli protein (YbeL) to the N and C termini in E. coli, yielding His-YbeL-PfCRT-YbeL-His, which was used throughout this study (28, 29) . We obtained a protein fraction containing three major protein bands on SDS-polyacrylamide gel electrophoresis (SDS/PAGE) (Fig. 1A) . Western blotting analysis indicated that the major polypeptide with apparent molecular mass of 72 kDa was a PfCRT protein, and the lowermolecular-weight protein band was a proteolytic product ( Fig.  1A and SI Appendix, Table S1 ).
Significance
Malaria caused by Plasmodium falciparum is a severe infectious disease with high mortality and morbidity rates worldwide. Chloroquine (CQ) is a widely used antimalarial agent, but the emergence and spread of CQ-resistant parasites is a growing global health problem. Although its physiological relevance remains unknown, P. falciparum CQ resistance transporter (PfCRT) confers CQ resistance through CQ egress from digestive vacuoles of P. falciparum. To address this issue, recombinant CQ-sensitive or CQ-resistant PfCRT proteins were purified and their transport activities were assessed. Both CQ-sensitive and CQ-resistant PfCRTs transported CQ, various antimalarial agents, and basic amino acids, indicating that PfCRT is a polyspecific drug and nutrient exporter.
Accordingly, we established ΔpH and Δψ by the pH jump method and K + diffusion potential with the K + -selective ionophore, valinomycin, across the liposomal membranes (30) . Liposomes containing PfCRT actively took up tetraethyl ammonium (TEA), a typical substrate for polyspecific organic cation transporters (31, 32) , when both the outside-acidic ΔpH and outside-positive Δψ were applied (Fig. 1B) . Bioenergetic analysis indicated that both ΔpH and Δψ were necessary for full uptake, and either Δψ or ΔpH alone resulted in low levels of TEA uptake (Fig. 1C) . Opposite ΔpH, i.e., inside-acidic ΔpH or inside-positive Δψ, exhibited the background level of uptake and did not drive active transport. Neither Na + nor K + gradients were effective. The ΔpH-and Δψ-driven TEA uptake showed an ordinary Michaelis-Menten type saturation curve with K m = 1.58 mM and V max = 371 nmol/min/mg protein, respectively (Fig. 1D ). To date, eight individual mutations have been found in CQ-resistant PfCRTs (2, 8, (33) (34) (35) (36) (37) (38) . Among them, we expressed and purified two CQ-resistant PfCRTs (PfCRT 7G8 and PfCRT Dd2 ) and PfCRT with a K76T mutation in the 3D7 background, PfCRT K76T , which is conserved in known resistant PfCRTs, and examined their TEA uptake capabilities (Fig. 1E) (2, 8, (33) (34) (35) (36) (37) (38) . The results indicated that all CQ-resistant PfCRTs also took up TEA, similar to CQ-sensitive PfCRT, although the activity tended to decrease in accordance with the degree of CQ resistance ( Fig. 1E and SI Appendix, Fig. S1 ). These results demonstrated that PfCRT is a ΔpH-and Δψ-driven TEA transporter.
Subsequently, we examined the detailed transport properties of PfCRT from cis-inhibition on TEA uptake by CQ-sensitive . After addition of valinomycin (2 μM) or DMSO (control), the uptake assay was started by adding radioactive TEA to a final concentration of 100 μM. Samples were obtained at the indicated times, and the TEA taken up by the liposomes was measured. The TEA uptake by the liposomes in the absence of valinomycin is also shown to indicate the background level. (C) Proteoliposomes were prepared in buffer containing 0.15 M Na + or K + at the indicated pH. Then, the proteoliposomes were incubated in buffer containing 0.15 M Na + or K + at the indicated pH, and TEA uptake after 1 min of incubation was measured. Asterisks indicate statistical significance. *P < 0.1, **P < 0.01. and CQ-resistant PfCRTs. The TEA uptake by CQ-sensitive PfCRT 3D7 was unaffected by neutral amino acids, acidic amino acids, and many organic anions (SI Appendix, Fig. S2 ). Consistent with these observations, PfCRT did not transport glutamic acids, GABA, leucine, L-serine, or p-aminohippuric acid (SI Appendix, Fig. S3 ). However, the TEA uptake by CQ-sensitive PfCRT 3D7 was strongly inhibited by inhibitors of PfCRT, such as verapamil and quinidine, as well as CQ, and nutrients, such as arginine, lysine, and peptides ( Fig. 2A) . Histidine also showed a strong inhibitory effect, whereas tryptophan had a weak effect. TEA uptake by PfCRT 3D7 was also inhibited by dequalinium, Hoechst 33342, and rhodamine 123, which are typical substrates for multidrug transporters (SI Appendix, Fig. S4 ). In addition to TEA, we found that PfCRT 3D7 transports cimetidine, histamine, and spermidine (SI Appendix, Fig. S5 ). These results suggested that PfCRT 3D7 is a polyspecific transporter that can recognize a wide range of substrates, including organic cations, basic amino acids, polyamines, and peptides derived from the degradation of hemoglobin. Unexpectedly, aside from some exceptions, such as histidine, these compounds were not effective in inhibition of TEA uptake by PfCRT K76T or CQ-resistant PfCRT 7G8 and PfCRT
Dd2
, and their ineffectiveness tended to increase in accordance with the degree of resistance (Fig. 2 B-D) . These observations suggest that CQ-resistant PfCRTs may have lost the ability to recognize these compounds as substrates and can no longer transport them or that CQ-resistant PfCRTs may have altered affinities to these compounds, resulting in changes in their kinetic parameters for these substrates.
Next, we investigated the mechanisms underlying the different responses between CQ-sensitive and CQ-resistant PfCRTs in cis-inhibition. We focused on CQ uptake by PfCRTs because oocytes of Xenopus laevis expressing resistant PfCRT Dd2 were reported to take up CQ, whereas oocytes expressing CQ-sensitive PfCRT 3D7 did not (16) . In reconstituted liposomes, CQsensitive PfCRT 3D7 showed significant uptake of CQ ( Fig. 3 A  and B) . However, CQ-resistant PfCRTs exhibited an increase in CQ transport activity in accordance with the degree of resistance, with that in PfCRT
Dd2 showing a threefold increase (Fig. 3A) . Kinetic analysis of CQ uptake indicated that the increase in activity was due to a decrease in affinity to CQ (increase in K m value) and an increase in the V max of the transporter (Fig. 3 B and C) . Thus, the lack of an effect of CQ on TEA uptake in CQ-resistant PfCRTs was due to changes in kinetic properties. This implies that CQ is discharged from DV by PfCRT even in CQ-sensitive malaria parasites and that the amount of CQ discharged from DV is significantly increased in CQ-resistant variants.
As in the case of CQ uptake, quinidine and verapamil strongly inhibited TEA uptake by CQ-sensitive PfCRT 3D7 ( Fig. 2A) . Furthermore, these compounds had less effect on TEA uptake by CQ-resistant PfCRTs. We postulated that PfCRT would transport these chemicals with changes in the kinetic properties, as in the case of CQ. As anticipated, we found that PfCRT transported verapamil. The transport ability was increased in the resistant variants, although that of PfCRT Dd2 was slightly lower than that of PfCRT 7G8 (Fig. 3D) . Taken together, these results indicated that PfCRT functions as a polyspecific drug transporter similar to P-glycoprotein and MATE transporter (31, 32) .
Quinidine and verapamil are known to restore CQ sensitivity in CQ-resistant strains of P. falciparum (39) (40) (41) (42) (43) (44) (45) . Consistent with these observations, verapamil and quinidine inhibited CQ uptake by PfCRT 3D7 and PfCRT Dd2 , respectively, although the extent of inhibition of CQ uptake by PfCRT Dd2 was weak (Fig. 3E ). These observations indicated that these agents are competitive inhibitors of PfCRT and inhibit CQ transport regardless of sensitivity to CQ. Although CQ uptake by CQ-resistant PfCRTs was inhibited by verapamil, CQ transport activity in the presence of verapamil was still higher than that of CQ-sensitive PfCRT 3D7 due to increased CQ transport activity in the resistant strains. This may explain why the CQ susceptibility of CQ-resistant strains in the presence of verapamil is still lower than that of CQ-sensitive strains (39) .
The most important characteristic of PfCRT that can be inferred from the analysis of TEA uptake is that it is inhibited by basic amino acids, such as arginine or lysine, and by peptides, suggesting that PfCRT transports basic amino acids and peptides (Fig. 2) . We measured the uptake of radiolabeled amino acids by PfCRTs. As expected, PfCRTs transported arginine in a ΔpH-and Δψ-dependent manner with K m and V max of 0.57 mM and 44.7 nmol/min/mg protein for PfCRT , respectively ( Fig. 4C and SI Appendix, Fig. S9 ). Moreover, CQ strongly inhibited the transport of these amino acids, whereas this inhibition in CQ-resistant PfCRT Dd2 was relatively weak (Fig. 4 D and E) . Based on the information regarding the transport properties presented here, we concluded that PfCRT possesses two significant activities as a polyspecific drug exporter and a polyspecific V V Y P W T Q R F V e r a p a m il Q u in id in e 1 µ M C h lo r o q u in e nutrient exporter. PfCRT exports CQ and organic amine drugs, such as verapamil, from the DV. K76T is a common mutation in CQ-resistant strains and is the most important mutation for CQ susceptibility (8) . In agreement with detailed drug susceptibility testing reported by Johnson et al. (46), our results indicate that the K76T mutation confers CQ insensitivity but does not provide sufficient CQ resistance without other mutations found in Dd2 and 7G8. The CQ-resistant variant showed decreased affinity to CQ and increased transport, which caused a decrease in CQ level inside the vacuole, thus resulting in resistance. The observation that PfCRT transports amino acids and peptides, which are generated in the DV, suggests a physiological role of PfCRT in nutrient supply (SI Appendix, Fig. S10 ). It is possible that inhibition of amino acid transport by CQ is correlated with its antimalarial effect, and this should be examined in future studies. The observation that PfCRT recognizes a variety of cationic substrates, similar to polyspecific drug transporters, suggests that inhibitors of multidrug transporters may be good candidates for antimalarial drug discovery.
The functions of PfCRT clarified in this study provide insight into overcoming drug resistance by malaria parasites: noncompetitive inhibitors of PfCRT, such as quinine dimers, may inhibit both export of CQ and supply of nutrients and thus result in the development of more potent drugs that may cause malfunction of the DV (47) . The assay system used in this study with purified PfCRT will be useful in screening for such drugs.
Materials and Methods
Construction of PfCRT Expression Vectors. A cDNA encoding CQ-sensitive PfCRT 3D7 was synthesized with optimized codons using the OptimumGene algorithm for expression in E. coli (GenScript). The codon adaptation index and GC contents of synthesized cDNA were 0.88% and 45%, respectively, and did not contain a Shine-Dalgarno sequence. The synthesized cDNA was amplified by PCR with the forward primer 5′-CGGGGGATCCGAATTCATGA-AATTCGCAAGTAAAAA-3′ and the reverse primer 5′-CCTTGTTCATCTCGAG-TTGGGTAATGATGCTGTCCA-3′. The amplified DNA fragment was cloned into an expression vector using an infusion cloning kit (TaKaRa). β-pET-28a(+)-β, which was designed for overexpression of eukaryotic membrane proteins in E. coli, was used in this study (28) . The resultant plasmid was named "pET-βpfCRT 3D7 -β."
Expression plasmids encoding CQ-resistant PfCRTs were generated by sitedirected mutagenesis using a plasmid encoding PfCRT 3D7 . The expression plasmids harboring 7G8 (C72S/K76T/A220S/N326D/I356L), Dd2 (M74I/N75E/ K76T/A220S/Q271E/N326S/I356T/R371I), or K76T were constructed using the following primer pairs: K76T, forward-5′-AATACCATCTTTGCGAAACGCAC-GCTGAACAAAAT-3′, reverse-5′-CGCAAAGATGGTATTCATAACGC)-3′; M74I and N75E, forward-5′-CCGTGTGCGTTATTGAAACCATCTTTGCGA-3′, reverse-5′-TCGCAAAGATGGTTTCAATAACGCACACGG-3′; A220S, forward-5′-TGGTCCTG-ATCAGCAGCCTGATTCCGGTGT, reverse-5′-ACACCGGAATCAGGCTGCTGATCAGG-ACCA-3′; Q271E, forward-5′-GCCGTTTCTGAAAGAACTGCACCTGCCGTA-3′, reverse-5′-TGTTTAGCTTTTTCAGCATCTGCGATAATC-3′; N326S, forward-5′-TGTTTAGCTTTTTCAGCATCTGCGATAATC-3′, reverse-5′-GATTATCGCAGA-TGCTGAAAAAGCTAAACA-3′; I356T, forward-5′-CAGGGTCCGGCGACCGC-CATTGCATATTAC-3′, reverse-5′-GTAATATGCAATGGCGGTCGCCGGACCCTG-3′; and R371I, forward-5′-CCGGCGATGTTGTCATTGAACCGCGCCTGC-3′, reverse-5′-GCAGGCGCGGTTCAATGACAACATCGCCGG-3′.
Expression and Purification of PfCRT. The protocol used was essentially the same as that described previously by Leviatan et al. (28) . The expression vector was transformed into E. coli C43 (DE3) cells. Transformed cells were grown in Terrific Broth medium containing 20 μg/mL kanamycin sulfate until OD 600 = 0.6-0.8, and then isopropyl β-D-thiogalactopyranoside was added at a final concentration of 1 mM. After incubation for 16 h at 18°C, cells were harvested by centrifugation and suspended in buffer containing 20 mM Tris·HCl (pH 7.5), 100 mM NaCl, 10 mM KCl, and 2 mM phenylmethylsulfonyl fluoride (PMSF). The cell suspension was then disrupted by sonication with a Tomy UD 200 tip sonifier at OUTPUT level 4 (Tomy). To remove large inclusion bodies and cell debris, the suspension was centrifuged at 5,856 × g at 4°C for 10 min, and the supernatant was then recentrifuged at 150,000 × g for 1 h at 4°C. The pellet was suspended and adjusted to 10 mg/mL with the same buffer, followed by addition of 1.5% (wt/vol) Fos-choline 14 (Affymetrix) and centrifuged at 150,000 × g at 4°C for 1 h. The supernatant containing PfCRT was obtained, diluted twofold with buffer consisting of 20 mM Tris·HCl (pH 7.5), 100 mM NaCl, 10 mM KCl, and 2 mM PMSF, and then applied to a column containing 1 mL of nickel-NTA Superflow resin (Qiagen) equilibrated with a buffer consisting of 20 mM Tris·HCl (pH 8.0), 100 mM NaCl, and 10 mM KCl. After protein binding, the column was washed with washing buffer consisting of 20 mM Tris·HCl (pH 8.0), 20 mM imidazole, 100 mM NaCl, 10 mM KCl, and 1% octyl glucoside (Dojin). The PfCRT protein was eluted with buffer consisting of 20 mM Tris·HCl (pH 8.0), 300 mM imidazole, 100 mM NaCl, 10 mM KCl, and 1% octyl glucoside and then stored at -80°C, at which temperature it was stable without loss of activity for at least several months.
Reconstitution. Purified PfCRT was reconstituted into proteoliposomes using the freeze-thaw method described previously (28) . Briefly, 20 μg of purified PfCRT was mixed with liposomes (0.5 mg lipid), frozen at -80°C, and then left at this temperature for at least 10 min. The mixture was then thawed quickly and diluted 60-fold with reconstitution buffer consisting of 20 mM Tricine-KOH (pH 8.0), 5 mM magnesium chloride, and 100 mM KCl. Proteoliposomes were precipitated by centrifugation at 200,000 × g for 1 h at 4°C and suspended in 0.4 mL of reconstitution buffer.
Transporter Assay. The transporter assay was carried out as described previously (28) . Briefly, proteoliposomes (∼1.5 μg of reconstituted protein/assay) were suspended in high pH buffer containing 20 mM tricine-KOH (pH 8.0), 5 mM magnesium chloride, and 100 mM NaCl or in low pH buffer containing 20 mM MES-KOH (pH 6.0), 5 mM magnesium chloride, 100 mM KCl, and 2 μM valinomycin and then incubated for a further 3 min at 27°C. The assay was initiated by addition of 100 μM [1- uptake was measured at 100 μM unless otherwise indicated. Protein concentration was determined using BSA as a standard.
Mass Spectrometric Analysis of Purified PfCRT Protein. Peptides of purified PfCRT fraction were analyzed according to the manufacturer's protocol. Briefly, protein bands separated by SDS/PAGE were dissected out from the gels and washed with 25 mM NaHCO 3 , 50-30% (vol/vol) acetonitrile. After removal of acetonitrile by evaporation, samples were reduced by addition of 10 mM DTT and then alkylated by 55 mM iodoacetamide. In-gel digestion was performed with 5 mg/mL trypsin (Promega) at 37°C for 24 h. Samples were concentrated by evaporation and were spotted onto an MTP AnchorChip 600/384 TF plate using the thin-layer affinity α-cyano-4-hydroxycinnamic acid AnchorChip preparation method. Mass spectrometric analysis was performed with an UltrafleXtreme MALDI-TOF/TOF-Mass Spectrometer system (Bruker Daltonics). The mass spectrometer was externally calibrated using peptide calibration standard II (Bruker Daltonics). Peptide masses were acquired with a range of 300-6,000 m/z. The MS/MS spectra were assigned using BioTools software v.3.2.1 (Bruker Daltonics), and the results were searched for matches to the PfCRT protein sequence by the Mascot search engine (Matrix Science).
Miscellaneous Procedures. Site-specific rabbit polyclonal antibodies against PfCRT were prepared by repeated injection of GST fusion polypeptides encoding amino acid residues M1-L35 of the N terminus of PfCRT. Polyacrylamide gel electrophoresis in the presence of SDS and Western blotting was performed as described previously (28) .
Data Analysis. All numerical values are shown as the means ± SEM; n = 3-6, unless otherwise specified. Results were analyzed by Student's t test.
